Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 546 | 63527-52-6 |
Dose | Unit | Route |
---|---|---|
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 30 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 376.38 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.60 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 11, 1981 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 199.82 | 26.88 | 81 | 4607 | 28343 | 50572093 |
Hepatocellular injury | 101.36 | 26.88 | 49 | 4639 | 25898 | 50574538 |
Eosinophilia | 87.56 | 26.88 | 40 | 4648 | 18612 | 50581824 |
Premature baby | 85.06 | 26.88 | 39 | 4649 | 18298 | 50582138 |
Toxic epidermal necrolysis | 77.04 | 26.88 | 38 | 4650 | 20954 | 50579482 |
Rash maculo-papular | 65.77 | 26.88 | 37 | 4651 | 26604 | 50573832 |
Pyrexia | 64.35 | 26.88 | 121 | 4567 | 380082 | 50220354 |
Septic shock | 63.29 | 26.88 | 48 | 4640 | 57127 | 50543309 |
Patent ductus arteriosus | 61.09 | 26.88 | 20 | 4668 | 3800 | 50596636 |
Acute generalised exanthematous pustulosis | 57.69 | 26.88 | 24 | 4664 | 8914 | 50591522 |
Laryngeal stenosis | 54.31 | 26.88 | 13 | 4675 | 784 | 50599652 |
Purpura | 52.05 | 26.88 | 23 | 4665 | 9888 | 50590548 |
Foetal exposure during pregnancy | 49.25 | 26.88 | 31 | 4657 | 27328 | 50573108 |
Umbilical erythema | 47.89 | 26.88 | 8 | 4680 | 72 | 50600364 |
Fatigue | 45.59 | 26.88 | 6 | 4682 | 707595 | 49892841 |
Agranulocytosis | 45.54 | 26.88 | 27 | 4661 | 21394 | 50579042 |
Hydrocephalus | 45.46 | 26.88 | 17 | 4671 | 4771 | 50595665 |
Necrosis | 42.01 | 26.88 | 16 | 4672 | 4720 | 50595716 |
Encephalopathy | 38.82 | 26.88 | 29 | 4659 | 33682 | 50566754 |
Subperiosteal abscess | 37.97 | 26.88 | 5 | 4683 | 5 | 50600431 |
Thrombocytopenia | 35.52 | 26.88 | 51 | 4637 | 127622 | 50472814 |
Ventricular dysfunction | 35.06 | 26.88 | 12 | 4676 | 2609 | 50597827 |
Lactic acidosis | 34.68 | 26.88 | 27 | 4661 | 33328 | 50567108 |
Multiple organ dysfunction syndrome | 34.38 | 26.88 | 32 | 4656 | 50305 | 50550131 |
Acute kidney injury | 34.04 | 26.88 | 69 | 4619 | 227989 | 50372447 |
Death neonatal | 33.53 | 26.88 | 7 | 4681 | 225 | 50600211 |
Toxic shock syndrome streptococcal | 32.79 | 26.88 | 6 | 4682 | 95 | 50600341 |
Haemophagocytic lymphohistiocytosis | 32.76 | 26.88 | 16 | 4672 | 8617 | 50591819 |
Stenotrophomonas infection | 31.86 | 26.88 | 10 | 4678 | 1659 | 50598777 |
Cholestasis | 31.83 | 26.88 | 23 | 4665 | 25378 | 50575058 |
Pulmonary necrosis | 31.76 | 26.88 | 6 | 4682 | 114 | 50600322 |
Central nervous system necrosis | 30.88 | 26.88 | 6 | 4682 | 133 | 50600303 |
Cross sensitivity reaction | 30.23 | 26.88 | 10 | 4678 | 1959 | 50598477 |
Petechiae | 29.84 | 26.88 | 17 | 4671 | 12495 | 50587941 |
Oligohydramnios | 29.08 | 26.88 | 13 | 4675 | 5737 | 50594699 |
Hepatic failure | 29.02 | 26.88 | 24 | 4664 | 32259 | 50568177 |
Hyperleukocytosis | 28.70 | 26.88 | 7 | 4681 | 457 | 50599979 |
Respiratory acidosis | 28.49 | 26.88 | 13 | 4675 | 6015 | 50594421 |
Disseminated intravascular coagulation | 27.33 | 26.88 | 18 | 4670 | 17117 | 50583319 |
Brain abscess | 27.12 | 26.88 | 9 | 4679 | 1782 | 50598654 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 295.03 | 25.04 | 132 | 5650 | 27860 | 29540885 |
Rash maculo-papular | 151.17 | 25.04 | 80 | 5702 | 24209 | 29544536 |
Hepatocellular injury | 143.71 | 25.04 | 74 | 5708 | 21169 | 29547576 |
Eosinophilia | 104.94 | 25.04 | 61 | 5721 | 22100 | 29546645 |
Toxic epidermal necrolysis | 80.74 | 25.04 | 48 | 5734 | 18105 | 29550640 |
Agranulocytosis | 56.43 | 25.04 | 40 | 5742 | 20300 | 29548445 |
Acute kidney injury | 55.67 | 25.04 | 144 | 5638 | 265123 | 29303622 |
Haemophagocytic lymphohistiocytosis | 55.27 | 25.04 | 31 | 5751 | 10473 | 29558272 |
Toxic skin eruption | 54.64 | 25.04 | 30 | 5752 | 9727 | 29559018 |
Clostridium difficile colitis | 53.73 | 25.04 | 33 | 5749 | 13179 | 29555566 |
Cholestasis | 49.16 | 25.04 | 39 | 5743 | 23423 | 29545322 |
Urethral valves | 47.28 | 25.04 | 11 | 5771 | 272 | 29568473 |
Purpura | 45.21 | 25.04 | 26 | 5756 | 9206 | 29559539 |
Thrombotic microangiopathy | 41.32 | 25.04 | 24 | 5758 | 8657 | 29560088 |
Pyrexia | 38.24 | 25.04 | 133 | 5649 | 287489 | 29281256 |
Neutropenia | 37.84 | 25.04 | 81 | 5701 | 131630 | 29437115 |
Klebsiella infection | 36.79 | 25.04 | 21 | 5761 | 7328 | 29561417 |
Mixed liver injury | 32.64 | 25.04 | 13 | 5769 | 2038 | 29566707 |
Haematoma muscle | 29.98 | 25.04 | 10 | 5772 | 947 | 29567798 |
Nausea | 29.41 | 25.04 | 10 | 5772 | 289245 | 29279500 |
ADAMTS13 activity decreased | 29.22 | 25.04 | 6 | 5776 | 81 | 29568664 |
Rash | 28.90 | 25.04 | 92 | 5690 | 189727 | 29379018 |
Systemic candida | 28.83 | 25.04 | 13 | 5769 | 2767 | 29565978 |
Septic shock | 28.61 | 25.04 | 47 | 5735 | 62513 | 29506232 |
Respiratory gas exchange disorder | 28.33 | 25.04 | 8 | 5774 | 433 | 29568312 |
Death | 28.22 | 25.04 | 16 | 5766 | 342068 | 29226677 |
Red blood cell schistocytes present | 28.03 | 25.04 | 7 | 5775 | 235 | 29568510 |
Thrombocytopenia | 27.91 | 25.04 | 73 | 5709 | 134750 | 29433995 |
Fatigue | 27.32 | 25.04 | 14 | 5768 | 316807 | 29251938 |
Bicytopenia | 27.07 | 25.04 | 11 | 5771 | 1816 | 29566929 |
Hepatic cytolysis | 26.87 | 25.04 | 18 | 5764 | 8329 | 29560416 |
Drug ineffective | 26.47 | 25.04 | 140 | 5642 | 363030 | 29205715 |
Gamma-glutamyltransferase increased | 25.97 | 25.04 | 29 | 5753 | 26708 | 29542037 |
Vasculitis necrotising | 25.84 | 25.04 | 8 | 5774 | 597 | 29568148 |
Face oedema | 25.71 | 25.04 | 19 | 5763 | 10264 | 29558481 |
Acute generalised exanthematous pustulosis | 25.42 | 25.04 | 15 | 5767 | 5568 | 29563177 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 488.28 | 22.04 | 208 | 8919 | 54009 | 64435596 |
Hepatocellular injury | 235.90 | 22.04 | 119 | 9008 | 45116 | 64444489 |
Rash maculo-papular | 220.01 | 22.04 | 115 | 9012 | 46911 | 64442694 |
Eosinophilia | 197.98 | 22.04 | 100 | 9027 | 37976 | 64451629 |
Toxic epidermal necrolysis | 154.35 | 22.04 | 84 | 9043 | 37082 | 64452523 |
Agranulocytosis | 104.71 | 22.04 | 66 | 9061 | 38163 | 64451442 |
Purpura | 97.55 | 22.04 | 48 | 9079 | 17198 | 64472407 |
Pyrexia | 94.87 | 22.04 | 229 | 8898 | 558415 | 63931190 |
Acute kidney injury | 82.48 | 22.04 | 190 | 8937 | 449050 | 64040555 |
Toxic skin eruption | 78.38 | 22.04 | 43 | 9084 | 19241 | 64470364 |
Cholestasis | 72.39 | 22.04 | 56 | 9071 | 44816 | 64444789 |
Septic shock | 67.82 | 22.04 | 79 | 9048 | 105358 | 64384247 |
Clostridium difficile colitis | 64.68 | 22.04 | 43 | 9084 | 27180 | 64462425 |
Fatigue | 62.08 | 22.04 | 15 | 9112 | 748715 | 63740890 |
Acute generalised exanthematous pustulosis | 61.73 | 22.04 | 33 | 9094 | 14025 | 64475580 |
Thrombocytopenia | 57.72 | 22.04 | 109 | 9018 | 223692 | 64265913 |
Haemophagocytic lymphohistiocytosis | 57.40 | 22.04 | 34 | 9093 | 17575 | 64472030 |
Neutropenia | 53.68 | 22.04 | 110 | 9017 | 239514 | 64250091 |
Encephalopathy | 51.70 | 22.04 | 52 | 9075 | 58767 | 64430838 |
Laryngeal stenosis | 48.68 | 22.04 | 13 | 9114 | 794 | 64488811 |
Pseudomembranous colitis | 44.55 | 22.04 | 19 | 9108 | 4897 | 64484708 |
Cross sensitivity reaction | 44.26 | 22.04 | 17 | 9110 | 3350 | 64486255 |
Pain | 44.06 | 22.04 | 12 | 9115 | 553499 | 63936106 |
Thrombotic microangiopathy | 43.69 | 22.04 | 28 | 9099 | 16627 | 64472978 |
Nausea | 43.59 | 22.04 | 29 | 9098 | 785771 | 63703834 |
Mixed liver injury | 42.57 | 22.04 | 19 | 9108 | 5462 | 64484143 |
Dermatitis bullous | 38.57 | 22.04 | 23 | 9104 | 12031 | 64477574 |
Hepatic cytolysis | 37.80 | 22.04 | 24 | 9103 | 14025 | 64475580 |
Multiple organ dysfunction syndrome | 33.34 | 22.04 | 55 | 9072 | 101358 | 64388247 |
Hyperbilirubinaemia | 33.17 | 22.04 | 26 | 9101 | 21179 | 64468426 |
Hydrocephalus | 31.04 | 22.04 | 17 | 9110 | 7574 | 64482031 |
Arthralgia | 30.91 | 22.04 | 12 | 9115 | 442248 | 64047357 |
Anaphylactic shock | 30.73 | 22.04 | 29 | 9098 | 30299 | 64459306 |
Bicytopenia | 29.55 | 22.04 | 13 | 9114 | 3609 | 64485996 |
Klebsiella infection | 29.19 | 22.04 | 20 | 9107 | 13261 | 64476344 |
Red blood cell schistocytes present | 29.14 | 22.04 | 8 | 9119 | 542 | 64489063 |
Subperiosteal abscess | 28.56 | 22.04 | 5 | 9122 | 38 | 64489567 |
Hepatic failure | 28.30 | 22.04 | 37 | 9090 | 55357 | 64434248 |
Ventricular dysfunction | 27.81 | 22.04 | 14 | 9113 | 5256 | 64484349 |
ADAMTS13 activity decreased | 27.47 | 22.04 | 6 | 9121 | 155 | 64489450 |
Haematoma muscle | 27 | 22.04 | 10 | 9117 | 1783 | 64487822 |
Respiratory gas exchange disorder | 26.53 | 22.04 | 8 | 9119 | 757 | 64488848 |
Brain oedema | 26.06 | 22.04 | 23 | 9104 | 22052 | 64467553 |
Stevens-Johnson syndrome | 25.99 | 22.04 | 28 | 9099 | 34221 | 64455384 |
Neutrophil count increased | 25.37 | 22.04 | 24 | 9103 | 25150 | 64464455 |
Rash | 24.76 | 22.04 | 129 | 8998 | 458420 | 64031185 |
Gamma-glutamyltransferase increased | 24.16 | 22.04 | 32 | 9095 | 48478 | 64441127 |
CD4 lymphocytes increased | 24.14 | 22.04 | 6 | 9121 | 275 | 64489330 |
Central nervous system necrosis | 24.08 | 22.04 | 6 | 9121 | 278 | 64489327 |
Vasculitis necrotising | 23.88 | 22.04 | 8 | 9119 | 1064 | 64488541 |
Enterococcal infection | 23.87 | 22.04 | 18 | 9109 | 13848 | 64475757 |
HIV associated nephropathy | 23.73 | 22.04 | 6 | 9121 | 295 | 64489310 |
Erythema | 23.68 | 22.04 | 69 | 9058 | 187001 | 64302604 |
Mucormycosis | 23.46 | 22.04 | 14 | 9113 | 7327 | 64482278 |
Hyperlactacidaemia | 23.04 | 22.04 | 12 | 9115 | 4832 | 64484773 |
CNS ventriculitis | 22.95 | 22.04 | 6 | 9121 | 337 | 64489268 |
None
Source | Code | Description |
---|---|---|
ATC | J01DD01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
ATC | J01DD51 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Streptococcal meningitis | indication | 4510004 | DOID:11574 |
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Streptococcal septicemia | indication | 29577008 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Neonatal conjunctivitis | indication | 34298002 | DOID:9699 |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Bacterial arthritis | indication | 48245008 | |
Peritonitis | indication | 48661000 | |
Lower respiratory tract infection | indication | 50417007 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Bacterial infection due to Serratia | indication | 71120004 | |
Septicemia due to Serratia | indication | 82091000 | |
Bacterial meningitis | indication | 95883001 | DOID:9470 |
Infection of bone | indication | 111253001 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Meningococcal meningitis | indication | 192644005 | |
Escherichia coli meningitis | indication | 192655005 | |
Proteus pneumonia | indication | 195888009 | |
Sepsis of the newborn | indication | 206376005 | |
Neonatal pneumonia | indication | 233619008 | |
Neonatal meningitis | indication | 276674008 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial urinary infection | indication | 312124009 | |
Meningitis due to Klebsiella mobilis | indication | 420585007 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Cesarean Section Infection Prevention | indication | ||
Streptococcal Peritonitis | indication | ||
E. Coli Peritonitis | indication | ||
E. Coli Endometritis | indication | ||
Haemophilus Influenzae Type B Infections | indication | ||
Neonatal Group B Streptococcal Septicemia | indication | ||
Klebsiella Endometritis | indication | ||
Proteus Endometritis | indication | ||
Enterococcus Pelvic Cellulitis | indication | ||
Prevention of Perioperative Infection | indication | ||
Proteus Mirabilis Osteomyelitis | indication | ||
Bacteroides Pelvic Cellulitis | indication | ||
Klebsiella Pelvic Inflammatory Disease | indication | ||
Staphylococcus Endometritis | indication | ||
H. Influenzae Meningitis | indication | ||
Clostridium Pelvic Inflammatory Disease | indication | ||
Haemophilus Parainfluenzae Pneumonia | indication | ||
Bacteroides Pelvic Inflammatory Disease | indication | ||
Staphylococcus Pelvic Inflammatory Disease | indication | ||
Proteus Peritonitis | indication | ||
Clostridium Endometritis | indication | ||
Staphylococcus Epidermidis Urinary Tract Infection | indication | ||
Enterococcus Pelvic Inflammatory Disease | indication | ||
Morganella Morganii Urinary Tract Infection | indication | ||
Fusobacterium Pelvic Inflammatory Disease | indication | ||
Streptococcus Osteomyelitis | indication | ||
Enterococcus Urinary Tract Infection | indication | ||
Clostridium Pelvic Cellulitis | indication | ||
Serratia Urinary Tract Infection | indication | ||
Enterobacter Pneumonia | indication | ||
Enterobacter Pelvic Inflammatory Disease | indication | ||
Bacteroides Endometritis | indication | ||
Providencia Urinary Tract Infection | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Fusobacterium Endometritis | indication | ||
Proteus Pelvic Inflammatory Disease | indication | ||
Clostridium Peritonitis | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
E. Coli Pelvic Cellulitis | indication | ||
Enterobacter Endometritis | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Enterococcus Endometritis | indication | ||
Pyrexia of unknown origin | off-label use | 7520000 | |
Acute gonococcal cervicitis | off-label use | 20943002 | DOID:10615 |
Lyme disease | off-label use | 23502006 | DOID:11729 |
Acute gonococcal urethritis | off-label use | 29864006 | |
Lyme arthritis | off-label use | 33937009 | |
Pseudotuberculosis | off-label use | 36753006 | |
Gonorrhea of rectum | off-label use | 42746002 | |
Lyme carditis | off-label use | 77863005 | |
Infection by Yersinia enterocolitica | off-label use | 80960004 | |
Ventilator-acquired pneumonia | off-label use | 429271009 | |
Disseminated Gonococcal Infection | off-label use | ||
Lyme Disease of the Central Nervous System | off-label use | ||
Acute nephropathy | contraindication | 58574008 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.39 | acidic |
pKa2 | 13.31 | acidic |
pKa3 | 3.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 6.24 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 6.51 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 5.66 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 2 | Enzyme | INHIBITOR | IC50 | 4.62 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | Ki | 6.30 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.60 | CHEMBL |
ID | Source |
---|---|
4019663 | VUID |
N0000147755 | NUI |
D00919 | KEGG_DRUG |
64485-93-4 | SECONDARY_CAS_RN |
203117 | RXNORM |
4018466 | VANDF |
4019663 | VANDF |
C0007554 | UMLSCUI |
CHEBI:3498 | CHEBI |
CE3 | PDB_CHEM_ID |
CHEMBL1010 | ChEMBL_ID |
CHEMBL1730 | ChEMBL_ID |
D002439 | MESH_DESCRIPTOR_UI |
DB00493 | DRUGBANK_ID |
10893 | IUPHAR_LIGAND_ID |
4504 | INN_ID |
N2GI8B1GK7 | UNII |
5742673 | PUBCHEM_CID |
42787 | MMSL |
4378 | MMSL |
d00008 | MMSL |
002727 | NDDF |
004845 | NDDF |
3334000 | SNOMEDCT_US |
372704003 | SNOMEDCT_US |
41722006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9930 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9931 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9933 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9935 | INJECTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-011 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-012 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-947 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 11 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-948 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 11 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-986 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 11 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-947 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 20 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-948 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 20 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-986 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |